{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:11:48Z","timestamp":1787501508708,"version":"build-2736575974"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01351-4","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T07:22:22Z","timestamp":1764228142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Radioembolization in Hepatocellular Carcinoma: Indications and Outcomes"],"prefix":"10.1007","volume":"56","author":[{"given":"Bahareh","family":"Gholami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Afrasiabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Villalobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Kokabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"3","key":"1351_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"1351_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"1351_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"2","key":"1351_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"B Sangro","year":"2025","unstructured":"Sangro B, Argemi J, Ronot M, Paradis V, Meyer T, Mazzaferro V, et al. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374.","journal-title":"J Hepatol"},{"issue":"32","key":"1351_CR5","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.3748\/wjg.v25.i32.4614","volume":"25","author":"R Inchingolo","year":"2019","unstructured":"Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: current evidence and future directions. World J Gastroenterol. 2019;25(32):4614\u201328.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1351_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.semradonc.2011.05.004","volume":"21","author":"K Memon","year":"2011","unstructured":"Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21(4):294\u2013302.","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"1351_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5306\/wjco.v9.i1.20","volume":"9","author":"MS Makary","year":"2018","unstructured":"Makary MS, Krishner LS, Wuthrick EJ, Bloomston MP, Dowell JD. Yttrium-90 microsphere selective internal radiation therapy for liver metastases following systemic chemotherapy and surgical resection for metastatic adrenocortical carcinoma. World J Clin Oncol. 2018;9(1):20.","journal-title":"World J Clin Oncol"},{"issue":"1","key":"1351_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"1351_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/00000658-199407000-00008","volume":"220","author":"JR Hiatt","year":"1994","unstructured":"Hiatt JR, Gabbay J, Busuttil RW. Surgical anatomy of the hepatic arteries in 1000 cases. Ann Surg. 1994;220(1):50\u20132.","journal-title":"Ann Surg"},{"issue":"3","key":"1351_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cpet.2025.03.002","volume":"20","author":"A Afrasiabi","year":"2025","unstructured":"Afrasiabi A, du Pisanie JL, Gholami B, Wang H, Gad S, Kokabi N. Post-Y90 PET dosimetry. PET Clin. 2025;20(3):291\u20138.","journal-title":"PET Clin"},{"issue":"4","key":"1351_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-0041-1732323","volume":"38","author":"LA Webster","year":"2021","unstructured":"Webster LA, Villalobos A, Majdalany BS, Bercu ZL, Gandhi RT, Kokabi N. Standard radiation dosimetry models: what interventional radiologists need to know. Semin Intervent Radiol. 2021;38(4):405\u201311.","journal-title":"Semin Intervent Radiol"},{"issue":"1","key":"1351_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-021-00394-3","volume":"8","author":"C Chiesa","year":"2021","unstructured":"Chiesa C, Sjogreen-Gleisner K, Walrand S, Strigari L, Flux G, Gear J, et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. EJNMMI Phys. 2021;8(1):77.","journal-title":"EJNMMI Phys"},{"key":"1351_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100633","author":"F Kolligs","year":"2023","unstructured":"Kolligs F, Arnold D, Golfieri R, Pech M, Peynircioglu B, Pfammatter T, et al. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study. JHEP Rep. 2023. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100633.","journal-title":"JHEP Rep"},{"issue":"1","key":"1351_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817744621","volume":"25","author":"ST Orcutt","year":"2018","unstructured":"Orcutt ST, Anaya DA. Liver resection and surgical strategies for management of primary liver cancer. Cancer Control. 2018;25(1):1073274817744621.","journal-title":"Cancer Control"},{"issue":"1","key":"1351_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2012.09.020","volume":"58","author":"Y-s Kim","year":"2013","unstructured":"Kim Y-s, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58(1):89\u201397.","journal-title":"J Hepatol"},{"issue":"1","key":"1351_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jvir.2017.08.026","volume":"29","author":"DM Biederman","year":"2018","unstructured":"Biederman DM, Titano JJ, Korff RA, Fischman AM, Patel RS, Nowakowski FS, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(1):30-e372.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"1351_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jhep.2017.10.004","volume":"68","author":"J-C Nault","year":"2018","unstructured":"Nault J-C, Sutter O, Nahon P, Ganne-Carri\u00e9 N, S\u00e9ror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018;68(4):783\u201397.","journal-title":"J Hepatol"},{"issue":"9","key":"1351_CR18","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1245\/s10434-017-5950-z","volume":"24","author":"F Pardo","year":"2017","unstructured":"Pardo F, Sangro B, Lee R-C, Manas D, Jeyarajah R, Donckier V, et al. The post-SIR-spheres surgery study (P4S): retrospective analysis of safety following hepatic resection or transplantation in patients previously treated with selective internal radiation therapy with Yttrium-90 resin microspheres. Ann Surg Oncol. 2017;24(9):2465\u201373.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1351_CR19","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74(5):2342\u201352.","journal-title":"Hepatology"},{"issue":"8","key":"1351_CR20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1097\/01.RVI.0000233785.75257.9A","volume":"17","author":"R Salem","year":"2006","unstructured":"Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17(8):1251\u201378.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1351_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","volume":"79","author":"A Riaz","year":"2011","unstructured":"Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79(1):163\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1351_CR22","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1148\/radiol.2018171768","volume":"287","author":"RJ Lewandowski","year":"2018","unstructured":"Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;287(3):1050\u20138.","journal-title":"Radiology"},{"issue":"1","key":"1351_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192\u2013201.","journal-title":"Hepatology"},{"issue":"9","key":"1351_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2468-1253(22)00091-7","volume":"7","author":"E Kim","year":"2022","unstructured":"Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022;7(9):843\u201350.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1351_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.01.005","author":"R Salem","year":"2025","unstructured":"Salem R, Padia SA, Toskich BB, Callahan JD, Fowers KD, Geller BS, et al. Radiation segmentectomy for early hepatocellular carcinoma is curative. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.005.","journal-title":"J Hepatol"},{"issue":"11","key":"1351_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199603143341104","volume":"334","author":"V Mazzaferro","year":"1996","unstructured":"Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693\u2013700.","journal-title":"N Engl J Med"},{"issue":"2","key":"1351_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","volume":"48","author":"A Gabr","year":"2021","unstructured":"Gabr A, Riaz A, Johnson GE, Kim E, Padia S, Lewandowski RJ, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol Imaging. 2021;48(2):580\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1351_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/lt.25381","volume":"25","author":"C Serra","year":"2019","unstructured":"Serra C, Cucchetti A, Felicani C, Mosconi C, De Cinque A, Golfieri R, et al. Assessment of radiofrequency ablation efficacy for hepatocellular carcinoma by histology and pretransplant radiology. Liver Transpl. 2019;25(1):88\u201397.","journal-title":"Liver Transpl"},{"issue":"11","key":"1351_CR29","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1007\/s00259-022-05776-y","volume":"49","author":"SA Montazeri","year":"2022","unstructured":"Montazeri SA, De la Garza-Ramos C, Lewis AR, Lewis JT, LeGout JD, Sella DM, Paz-Fumagalli R, Devcic Z, Ritchie CA, Frey GT, Vidal L, Croome KP, McKinney JM, Harnois D, Krishnan S, Patel T, Toskich BB. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging. 2022;49(11):3892\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1351_CR30","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231386","volume":"311","author":"A Sarwar","year":"2024","unstructured":"Sarwar A, Malik MS, Vo NH, Tsai LL, Tahir MM, Curry MP, et al. Efficacy and safety of radiation segmentectomy with (90)Y resin microspheres for hepatocellular carcinoma. Radiology. 2024;311(2):e231386.","journal-title":"Radiology"},{"issue":"8","key":"1351_CR31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00270-025-04113-8","volume":"48","author":"H Dabbous","year":"2025","unstructured":"Dabbous H, Gad S, Mohnasky M, Villalobos A, Brandon D, Xing M, et al. Tumor dose as an oncologic predictor of outcome in patients with HCC treated with resin Y90 microspheres. Cardiovasc Intervent Radiol. 2025;48(8):1113\u201325.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"9","key":"1351_CR32","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/RLU.0000000000005198","volume":"49","author":"N Kokabi","year":"2024","unstructured":"Kokabi N, Webster LA, Dabbous H, Shah A, Brandon D, Galt J, et al. Resin-based 90 Y tumor dose as a predictor of duration of response and survival in patients with surgically unresectable hepatocellular carcinoma: a prospective single-arm study. Clin Nucl Med. 2024;49(9):799\u2013805.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1351_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00879-x","volume":"12","author":"EB Veenstra","year":"2022","unstructured":"Veenstra EB, Ruiter SJS, de Haas RJ, Bokkers RPH, de Jong KP, Noordzij W. Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC. EJNMMI Res. 2022;12(1):9.","journal-title":"EJNMMI Res"},{"issue":"8","key":"1351_CR34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00270-025-04113-8","volume":"48","author":"H Dabbous","year":"2025","unstructured":"Dabbous H, Gad S, Mohnasky M, Villalobos A, Brandon D, Xing M, et al. Tumor dose as an oncologic predictor of outcome in patients with HCC treated with resin Y90 microspheres. Cardiovasc Intervent Radiol. 2025;48(8):1113\u201325.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"1351_CR35","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jvir.2022.03.021","volume":"33","author":"C De la Garza-Ramos","year":"2022","unstructured":"De la Garza-Ramos C, Montazeri SA, Croome KP, LeGout JD, Sella DM, Cleary S, Burns J, Mathur AK, Overfield CJ, Frey GT, Lewis AR, Paz-Fumagalli R, Ritchie CA, McKinney JM, Mody K, Patel T, Devcic Z, Toskich BB. Radiation segmentectomy for the treatment of solitary hepatocellular carcinoma: outcomes compared with those of surgical resection. J Vasc Interv Radiol. 2022;33(7):775\u2013e7852.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"1351_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1148\/radiol.2016160718","volume":"283","author":"DM Biederman","year":"2017","unstructured":"Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiology. 2017;283(3):895\u2013905.","journal-title":"Radiology"},{"issue":"3","key":"1351_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00270-020-02712-1","volume":"44","author":"L Arndt","year":"2021","unstructured":"Arndt L, Villalobos A, Wagstaff W, Cheng B, Xing M, Ermentrout RM, Bercu Z, Cristescu M, Shah A, Wedd J, Majdalany BS, Magliocca JF, Sellers MT, Kokabi N. Evaluation of Medium-Term efficacy of Y90 radiation segmentectomy vs percutaneous microwave ablation in patients with solitary surgically Unresectable\u2009<\u20094\u00a0cm hepatocellular carcinoma: A propensity score matched study. Cardiovasc Intervent Radiol. 2021;44(3):401\u201313.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1351_CR38","doi-asserted-by":"crossref","unstructured":"Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, Abecassis M, Fryer J, Salem R, Baker T. (90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99\u2013105.","DOI":"10.1002\/jso.24269"},{"issue":"5","key":"1351_CR39","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.surg.2020.12.012","volume":"169","author":"Y Bekki","year":"2021","unstructured":"Bekki Y, Marti J, Toshima T, Lewis S, Kamath A, Argiriadi P, et al. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. Surgery. 2021;169(5):1044\u201351.","journal-title":"Surgery"},{"key":"1351_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.yacr.2020.04.005","volume":"2","author":"A Gabr","year":"2020","unstructured":"Gabr A, Entezari P, Riaz A, Salem R, Lewandowski RJ. Contemporary techniques and applications of radioembolization in patients with hepatocellular carcinoma: Y90 from palliative to curative. Adv Clin Radiol. 2020;2:113\u201325.","journal-title":"Adv Clin Radiol"},{"issue":"4","key":"1351_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1055\/s-0039-1696648","volume":"36","author":"A Gabr","year":"2019","unstructured":"Gabr A, Riaz A, Mouli S, Desai K, Thornburg B, Salem R, Lewandowski RJ. Modified radiation lobectomy: an evolving paradigm to convert patients to liver resection candidacy. Semin Intervent Radiol. 2019;36(4):343\u20138.","journal-title":"Semin Intervent Radiol"},{"issue":"7","key":"1351_CR42","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jvir.2024.03.005","volume":"35","author":"Q Yu","year":"2024","unstructured":"Yu Q, Wang Y, Ungchusri E, Pillai A, Liao CY, Fung J, DiSabato D, Baker T, Patel M, Van Ha T, Ahmed O. Modified radiation lobectomy strategy of radioembolization for Right-Sided unresectable primary liver tumors. J Vasc Interv Radiol. 2024;35(7):989\u2013e9972.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"1351_CR43","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1097\/TP.0000000000003174","volume":"104","author":"N Mehta","year":"2020","unstructured":"Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, et al. Liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference. Transplantation. 2020;104(6):1136\u201342.","journal-title":"Transplantation"},{"key":"1351_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222313051","author":"C Ebeling Barbier","year":"2021","unstructured":"Ebeling Barbier C, Heindryckx F, Lennern\u00e4s H. Limitations and possibilities of transarterial chemotherapeutic treatment of hepatocellular carcinoma. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222313051.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1351_CR45","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/curroncol32090487","volume":"32","author":"B Gholami","year":"2025","unstructured":"Gholami B, Afrasiabi A, Moon AM, Yanagihara TK, Wang H, Gad S, Villalobos A, Mauro DM, Yu H, du Pisanie JL, Kokabi N. Safety of combination TARE and SBRT in hepatocellular carcinoma: A review of literature & Single-Center case series. Curr Oncol. 2025;32(9):487.","journal-title":"Curr Oncol"},{"issue":"4","key":"1351_CR46","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"20","key":"1351_CR47","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"8","key":"1351_CR48","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070.","journal-title":"NEJM Evid"},{"issue":"6","key":"1351_CR49","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jvir.2017.02.018","volume":"28","author":"SA Padia","year":"2017","unstructured":"Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, Vaidya S, Monsky WL, Park JO, Bhattacharya R, Hippe DS, Harris WP. Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a Single-Center, Retrospective, propensity Score-Matched study. J Vasc Interv Radiol. 2017;28(6):777\u2013e7851.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"1351_CR50","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.29691","volume":"68","author":"R Salem","year":"2018","unstructured":"Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. 2018;68(4):1429\u201340.","journal-title":"Hepatology"},{"issue":"3","key":"1351_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jvir.2024.11.012","volume":"36","author":"CD Malone","year":"2025","unstructured":"Malone CD, Bajaj S, He A, Mody K, Hickey RM, Sarwar A, Krishnan S, Patel TC, Toskich BB. Combining radioembolization and immune checkpoint inhibitors for the treatment of hepatocellular carcinoma: the quest for synergy. J Vasc Interv Radiol. 2025;36(3):414\u201324. e2.","journal-title":"J Vasc Interv Radiol"},{"key":"1351_CR52","first-page":"2025","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Xian L, Wang X, Liu Y, Li J. The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM. Front Immunol. 2025;16:2025.","journal-title":"Front Immunol"},{"issue":"5","key":"1351_CR53","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.23944","volume":"52","author":"P Hilgard","year":"2010","unstructured":"Hilgard P, Hamami M, Fouly AE, Scherag A, M\u00fcller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741\u20139.","journal-title":"Hepatology"},{"issue":"3","key":"1351_CR54","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868\u201378.","journal-title":"Hepatology"},{"issue":"1","key":"1351_CR55","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52\u201364.","journal-title":"Gastroenterology"},{"issue":"3","key":"1351_CR56","doi-asserted-by":"publisher","first-page":"398","DOI":"10.21037\/hbsn-24-151","volume":"14","author":"MA Meerun","year":"2025","unstructured":"Meerun MA, Allimant C, Schembri V, Hermida M, Latry-Kuhn C, Mariano-Goulart D, et al. Evaluating liver resection outcomes post Y90 TARE with personalized dosimetry in intermediate or advanced hepatocellular carcinoma: a focus on surgical and biliary complications. Hepatobiliary Surg Nutr. 2025;14(3):398\u2013410.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"8","key":"1351_CR57","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/1751-2980.13030","volume":"22","author":"C Martelletti","year":"2021","unstructured":"Martelletti C, Ricotti A, Gesualdo M, Carucci P, Gaia S, Rolle E, et al. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score and bayesian analysis. J Dig Dis. 2021;22(8):496\u2013502.","journal-title":"J Dig Dis"},{"key":"1351_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173024","author":"SY Son","year":"2024","unstructured":"Son SY, Geevarghese R, Marinelli B, Zhao K, Covey A, Maxwell A, et al. Conversion therapy to transplant or surgical resection in patients with unresectable hepatocellular carcinoma treated with boosted dose of Yttrium-90 radiation segmentectomy. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16173024.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1351_CR59","first-page":"158","volume":"14","author":"K Chen","year":"2025","unstructured":"Chen K, Tong AKT, Moe FNN, Ng DCE, Lo RHG, Gogna A, et al. The impact of radiation dose and tumour burden on outcomes in hepatocellular carcinoma: 11-year experience in a 413-patient cohort treated with Yttrium-90 resin microsphere radioembolisation. Liver Cancer. 2025;14(2):158\u201379.","journal-title":"Liver Cancer"},{"issue":"5","key":"1351_CR60","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/hep.26014","volume":"57","author":"V Mazzaferro","year":"2013","unstructured":"Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826\u201337.","journal-title":"Hepatology"},{"issue":"3","key":"1351_CR61","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3350\/cmh.2023.0076","volume":"29","author":"MH Hur","year":"2023","unstructured":"Hur MH, Cho Y, Kim DY, Lee JS, Kim GM, Kim HC, et al. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol. 2023;29(3):763\u201378.","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"1351_CR62","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00270-019-02404-5","volume":"43","author":"L Cardarelli-Leite","year":"2020","unstructured":"Cardarelli-Leite L, Chung J, Klass D, Marquez V, Chou F, Ho S, Walton H, Lim H, Tae Wan Kim P, Hadjivassiliou A, Liu DM. Ablative transarterial radioembolization improves survival in patients with HCC and portal vein tumor thrombus. Cardiovasc Intervent Radiol. 2020;43(3):411\u201322.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"1351_CR63","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jvir.2023.03.020","volume":"34","author":"H Briody","year":"2023","unstructured":"Briody H, Duong D, Yeoh SW, Hodgson R, Yong TL, Hannah A, et al. Radioembolization for treatment of hepatocellular carcinoma: current evidence and patterns of utilization. J Vasc Interv Radiol. 2023;34(7):1200\u201313.","journal-title":"J Vasc Interv Radiol"},{"issue":"19","key":"1351_CR64","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan S-B, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han H-S, Bae S-H, Yoon H-K, Lee R-C, Hung C-F, Peng C-Y, Liang P-C, Bartlett A, Kok KYY, Thng C-H, Low AS-C, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW. Soo, n. null, sirvenib: selective internal radiation therapy versus Sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913\u201321.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1351_CR65","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with Sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624\u201336.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1351_CR66","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/liv.12574","volume":"35","author":"A Gramenzi","year":"2015","unstructured":"Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, Cucchetti A, et al. Yttrium-90 radioembolization vs Sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 2015;35(3):1036\u201347.","journal-title":"Liver Int"},{"issue":"6","key":"1351_CR67","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164\u201374.","journal-title":"J Hepatol"},{"issue":"3","key":"1351_CR68","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jhep.2020.03.045","volume":"73","author":"M Reinders","year":"2020","unstructured":"Reinders M, Braat A, Lam M. Toxicity and dosimetry in SORAMIC study. J Hepatol. 2020;73(3):734\u20135.","journal-title":"J Hepatol"},{"issue":"6","key":"1351_CR69","doi-asserted-by":"publisher","first-page":"487","DOI":"10.21037\/hbsn.2018.10.06","volume":"7","author":"C Sposito","year":"2018","unstructured":"Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr. 2018;7(6):487\u20139.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"8","key":"1351_CR70","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2021","unstructured":"Sangro B, Sarobe P, Herv\u00e1s-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525\u201343.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"1351_CR71","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","volume":"68","author":"V Chew","year":"2019","unstructured":"Chew V, Lee YH, Pan L, Nasir NJ, Lim CJ, Chua C, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 2019;68(2):335\u201346.","journal-title":"Gut"},{"issue":"6","key":"1351_CR72","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s12328-024-02030-w","volume":"17","author":"T Nakabori","year":"2024","unstructured":"Nakabori T, Ikawa T, Kozumi K, Urabe M, Kai Y, Takada R, et al. Abscopal effect in a patient with advanced hepatocellular carcinoma upon resuming bevacizumab in combination with atezolizumab after radiotherapy. Clin J Gastroenterol. 2024;17(6):1053\u20137.","journal-title":"Clin J Gastroenterol"},{"issue":"12","key":"1351_CR73","doi-asserted-by":"publisher","first-page":"10100","DOI":"10.3390\/curroncol30120734","volume":"30","author":"A Villalobos","year":"2023","unstructured":"Villalobos A, Dabbous HH, Little O, Gbolahan OB, Akce M, Lilly MA, et al. Safety and efficacy of concurrent Atezolizumab\/Bevacizumab or nivolumab combination therapy with Yttrium-90 radioembolization of advanced unresectable hepatocellular carcinoma. Curr Oncol. 2023;30(12):10100\u201310.","journal-title":"Curr Oncol"},{"issue":"3","key":"1351_CR74","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","volume":"29","author":"S Yu","year":"2024","unstructured":"Yu S, Yu M, Keane B, Mauro DM, Helft PR, Harris WP, et al. A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma. Oncologist. 2024;29(3):270-e413.","journal-title":"Oncologist"},{"issue":"1","key":"1351_CR75","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","volume":"31","author":"C Zhan","year":"2020","unstructured":"Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, et al. Safety of combined Yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31(1):25\u201334.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"1351_CR76","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","volume":"6","author":"D Tai","year":"2021","unstructured":"Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, et al. Choo, radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209\u2013678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(12):1025\u201335.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1351_CR77","doi-asserted-by":"publisher","unstructured":"de la Torre-Al\u00e1ez M, Matilla A, Varela M, I\u00f1arrairaegui M, Reig M, Lled\u00f3 JL, Arenas JI, Lorente S, Testillano M, M\u00e1rquez L, Da Fonseca L, Argem\u00ed J, G\u00f3mez-Martin C, Rodriguez-Fraile M, Bilbao JI, Sangro B. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J Immunother Cancer. 2022;10(11). https:\/\/doi.org\/10.1136\/jitc-2022-005457.","DOI":"10.1136\/jitc-2022-005457"},{"issue":"12","key":"1351_CR78","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.14309\/ajg.0000000000002467","volume":"118","author":"YH Yeo","year":"2023","unstructured":"Yeo YH, Liang J, Lauzon M, Luu M, Noureddin M, Ayoub W, et al. Immunotherapy and transarterial radioembolization combination treatment for advanced hepatocellular carcinoma. Am J Gastroenterol. 2023;118(12):2201\u201311.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1351_CR79","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.211806","volume":"303","author":"E Dhondt","year":"2022","unstructured":"Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, et al. (90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699\u2013710.","journal-title":"Radiology"},{"issue":"2","key":"1351_CR80","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1016\/j.ijrobp.2024.07.1080","volume":"120","author":"R Iyer","year":"2024","unstructured":"Iyer R, Noonan A, Spieler B, White S, Kulik L, Underwood D, et al. EMERALD-Y90: a phase 2 study to evaluate transarterial radioembolization followed by durvalumab and bevacizumab for the treatment of unresectable hepatocellular carcinoma eligible for embolization. Int J Radiat Oncol Biol Phys. 2024;120(2):e487.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1351_CR81","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"J-W Park","year":"2015","unstructured":"Park J-W, Chen M, Colombo M, Roberts LR, Schwartz M, Chen P-J, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int. 2015;35(9):2155\u201366.","journal-title":"Liver Int"},{"issue":"6","key":"1351_CR82","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155-63. e2. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.029.","journal-title":"Gastroenterology"},{"issue":"8","key":"1351_CR83","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1111\/j.1600-6143.2009.02695.x","volume":"9","author":"RJ Lewandowski","year":"2009","unstructured":"Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920\u20138.","journal-title":"Am J Transplant"},{"issue":"1","key":"1351_CR84","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5604\/01.3001.0010.7542","volume":"17","author":"M Biolato","year":"2018","unstructured":"Biolato M, Gallusi G, Iavarone M, Cabibbo G, Racco S, De Santis A, et al. Prognostic ability of BCLC-B subclassification in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Hepatol. 2018;17(1):110\u20138.","journal-title":"Ann Hepatol"},{"issue":"10","key":"1351_CR85","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","volume":"11","author":"R Salem","year":"2013","unstructured":"Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB 3rd, Mulcahy MF, Kulik L, Lewandowski R. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11(10):1358\u2013e13651.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1351_CR86","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/liv.12750","volume":"35","author":"FT Kolligs","year":"2015","unstructured":"Kolligs FT, Bilbao JI, Jakobs T, I\u00f1arrairaegui M, Nagel JM, Rodriguez M, Haug A, D\u2019Avola D, op den Winkel M, Martinez-Cuesta A, Trumm C, Benito A, Tatsch K, Zech CJ, Hoffmann RT, Sangro B. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int. 2015;35(6):1715\u201321.","journal-title":"Liver Int"},{"issue":"2","key":"1351_CR87","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/liv.12637","volume":"35","author":"AE Fouly","year":"2015","unstructured":"Fouly AE, Ertle J, El Dorry A, Shaker MK, Dech\u00eane A, Abdella H, Mueller S, Barakat E, Lauenstein T, Bockisch A, Gerken G, Schlaak JF. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int. 2015;35(2):627\u201335.","journal-title":"Liver Int"},{"issue":"6","key":"1351_CR88","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jvir.2022.11.036","volume":"34","author":"S Ranganathan","year":"2023","unstructured":"Ranganathan S, Gabr A, Entezari P, Gordon AC, Riaz A, Desai K, et al. Radioembolization for intermediate-stage hepatocellular carcinoma maintains liver function and permits systemic therapy at progression. J Vasc Interv Radiol. 2023;34(6):968\u201375.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"1351_CR89","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1097\/TP.0000000000005204","volume":"109","author":"G Berardi","year":"2025","unstructured":"Berardi G, Guglielmo N, Cucchetti A, Usai S, Colasanti M, Meniconi RL, Ferretti S, Mariano G, Angrisani M, Sciuto R, Di Stefano F, Ventroni G, Riu P, Giannelli V, Pellicelli A, Lionetti R, D\u2019Offizi G, Vennarecci G, Maritti M, Tritapepe L, Cianni R. Ettorre, transarterial radioembolization can downstage intermediate and advanced hepatocellular carcinoma to liver transplantation. Transplantation. 2025;109(1):e54\u201363.","journal-title":"Transplantation"},{"issue":"3","key":"1351_CR90","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.211806","volume":"303","author":"E Dhondt","year":"2022","unstructured":"Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, Verhelst X, Aerts M, Vanlander A. Berrevoet, 90Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699\u2013710.","journal-title":"Radiology"},{"issue":"3","key":"1351_CR91","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1002\/cam4.5125","volume":"12","author":"AM Brown","year":"2023","unstructured":"Brown AM, Kassab I, Massani M, Townsend W, Singal AG, Soydal C, et al. TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis. Cancer Med. 2023;12(3):2590\u20139.","journal-title":"Cancer Med"},{"issue":"5","key":"1351_CR92","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/cncr.24884","volume":"116","author":"BI Carr","year":"2010","unstructured":"Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116(5):1305\u201314.","journal-title":"Cancer"},{"issue":"2","key":"1351_CR93","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jvir.2009.10.013","volume":"21","author":"DA Kooby","year":"2010","unstructured":"Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21(2):224\u201330.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"1351_CR94","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.jvir.2011.08.013","volume":"22","author":"C Lance","year":"2011","unstructured":"Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(12):1697\u2013705.","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"1351_CR95","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","volume":"140","author":"R Salem","year":"2011","unstructured":"Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497\u2013e5072.","journal-title":"Gastroenterology"},{"issue":"3","key":"1351_CR96","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","volume":"36","author":"LE Moreno-Luna","year":"2013","unstructured":"Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36(3):714\u201323.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"1351_CR97","first-page":"185","volume":"3","author":"WH She","year":"2014","unstructured":"She WH, Cheung TT, Yau TC, Chan AC, Chok KS, Chu FS, et al. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. Hepatobiliary Surg Nutr. 2014;3(4):185\u201393.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"1351_CR98","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","volume":"38","author":"MB Pitton","year":"2015","unstructured":"Pitton MB, Kloeckner R, Ruckes C, Wirth GM, Eichhorn W, W\u00f6rns MA, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2015;38(2):352\u201360.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"1351_CR99","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.suronc.2015.06.008","volume":"24","author":"O Akinwande","year":"2015","unstructured":"Akinwande O, Kim D, Edwards J, Brown R, Philips P, Scoggins C, et al. Is radioembolization (90Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Surg Oncol. 2015;24(3):270\u20135.","journal-title":"Surg Oncol"},{"key":"1351_CR100","doi-asserted-by":"crossref","unstructured":"Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155\u20131163.e2.","DOI":"10.1053\/j.gastro.2016.08.029"},{"issue":"10","key":"1351_CR101","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jvir.2017.05.017","volume":"28","author":"JL McDevitt","year":"2017","unstructured":"McDevitt JL, Alian A, Kapoor B, Bennett S, Gill A, Levitin A, et al. Single-center comparison of overall survival and toxicities in patients with infiltrative hepatocellular carcinoma treated with Yttrium-90 radioembolization or drug-eluting embolic transarterial chemoembolization. J Vasc Interv Radiol. 2017;28(10):1371\u20137.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"1351_CR102","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1007\/s00261-018-1802-y","volume":"44","author":"T Kirchner","year":"2019","unstructured":"Kirchner T, Marquardt S, Werncke T, Kirstein MM, Brunkhorst T, Wacker F, et al. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma. Abdom Radiol. 2019;44(4):1554\u201361.","journal-title":"Abdom Radiol"},{"issue":"11","key":"1351_CR103","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.diii.2019.05.006","volume":"100","author":"J Delicque","year":"2019","unstructured":"Delicque J, Hermida M, Piron L, Allimant C, Belgour A, Pageaux GP, et al. Intra arterial treatment of hepatocellular carcinoma: comparison of MELD score variations between radio-embolization and chemo-embolization. Diagn Interv Imaging. 2019;100(11):689\u201397.","journal-title":"Diagn Interv Imaging"},{"issue":"3","key":"1351_CR104","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s12029-020-00502-z","volume":"52","author":"RD Hirsch","year":"2021","unstructured":"Hirsch RD, Mills C, Sawhney R, Sood S, Bird V, Mishra G, et al. SIRT compared with DEB-TACE for hepatocellular carcinoma: a real-world study (the SITAR study). J Gastrointest Cancer. 2021;52(3):907\u201314.","journal-title":"J Gastrointest Cancer"},{"issue":"3","key":"1351_CR105","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/0284185120926474","volume":"62","author":"TA Auer","year":"2021","unstructured":"Auer TA, Jonczyk M, Collettini F, Marth A, Wieners G, Hamm B, et al. Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma. Acta Radiol. 2021;62(3):313\u201321.","journal-title":"Acta Radiol"},{"key":"1351_CR106","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2147\/JHC.S335879","volume":"8","author":"MA Kim","year":"2021","unstructured":"Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, et al. Yttrium-90 radioembolization is associated with better clinical outcomes in patients with hepatocellular carcinoma compared with conventional chemoembolization: a propensity score-matched study. J Hepatocell Carcinoma. 2021;8:1565\u201377.","journal-title":"J Hepatocell Carcinoma"},{"key":"1351_CR107","doi-asserted-by":"crossref","unstructured":"Chung SW, Cho H, Shin H, Park J, Kim JY, Hong JH, Hur MH, Park MK, Lee YB, Yu SJ, Lee M, Kim YJ, Paeng JC, Yoon J-H, Chung JW, Lee J-H, Kim H-C. Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients. Front Oncol. 2023; 13\u20132023.","DOI":"10.3389\/fonc.2023.1081479"},{"issue":"3","key":"1351_CR108","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1007\/s00261-024-04573-5","volume":"50","author":"NH Phan","year":"2025","unstructured":"Phan NH, Chun HJ, Oh JS, Kim SH, Choi BG. TACE vs. TARE for HCC\u2009\u2265\u20098\u00a0cm: A propensity score analysis. Abdom Radiol. 2025;50(3):1198\u2013208.","journal-title":"Abdom Radiol"},{"issue":"5","key":"1351_CR109","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2214\/AJR.22.28385","volume":"220","author":"A Sarwar","year":"2023","unstructured":"Sarwar A, Bonder A, Hassan L, Malik MS, Novack V, Curry M, et al. Factors associated with complete pathologic necrosis of hepatocellular carcinoma on explant evaluation after locoregional therapy: a National analysis using the UNOS database. AJR Am J Roentgenol. 2023;220(5):727\u201335.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"1351_CR110","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5582\/bst.2023.01322","volume":"17","author":"Y-n Ma","year":"2023","unstructured":"Ma Y-n, Jiang X, Liu H, Song P, Tang W. Conversion therapy for initially unresectable hepatocellular carcinoma: current status and prospects. Biosci Trends. 2023;17(6):415\u201326.","journal-title":"Biosci Trends"},{"issue":"3","key":"1351_CR111","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s11845-022-03131-6","volume":"192","author":"C Zhu","year":"2023","unstructured":"Zhu C, Dai B, Zhan H, Deng R. Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients. Ir J Med Sci. 2023;192(3):1065\u201371.","journal-title":"Ir J Med Sci"},{"issue":"6","key":"1351_CR112","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016;151(6):1155-e11632.","journal-title":"Gastroenterology"},{"key":"1351_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072122","author":"V Lopez-Lopez","year":"2023","unstructured":"Lopez-Lopez V, Miura K, Kuemmerli C, Capel A, Eshmuminov D, Ferreras D, et al. Selecting the appropriate downstaging and bridging therapies for hepatocellular carcinoma: what is the role of transarterial radioembolization? A pooled analysis. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15072122.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1351_CR114","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.31318","volume":"73","author":"A Gabr","year":"2021","unstructured":"Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, et al. Liver transplantation following Yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology. 2021;73(3):998\u20131010.","journal-title":"Hepatology"},{"issue":"2","key":"1351_CR115","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jvir.2024.10.021","volume":"36","author":"L Bonne","year":"2025","unstructured":"Bonne L, Deroose CM, Verslype C, Monbaliu D, Dekervel J, Van Laeken C, Vandecaveye V, Laenen A, Pirenne J. Maleux, Resin-Based Yttrium-90 radioembolization as a bridging or downstaging treatment to liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol. 2025;36(2):282\u201392.","journal-title":"J Vasc Interv Radiol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01351-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01351-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T09:03:12Z","timestamp":1764234192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01351-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":115,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1351"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01351-4","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"3 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kokabi is a consultant for SIRTeX Medical, Boston Scientific, Okami Medical, Terumo Medical, Trisalus Life SciencesDr. Villalobos is a consultant for SIRTeX Medical and Guerbett. Dr. Moon: Consultant for Intercept Pharmaceuticals, AstraZeneca, Eisai and IDEOlogy. Research funding (to institution) from DCN Diagnostics and Madrigal Pharmaceuticals.The remaining authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}